IGH (Immunoglobulin Heavy Locus)

News alerts, weekly reports and conference planners

Entrez ID:

3492

Related tests:

‹

LymphoTrack® Dx IGH Assay

Seq-MRD® assay

LymphoTrack® Dx IGH Assay

Seq-MRD® assay

›

IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	obinutuzumab Sensitive: A2 - Guideline obinutuzumab Sensitive : A2	obinutuzumab Sensitive: A2 - Guideline obinutuzumab Sensitive : A2
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A2 - Guideline venetoclax + obinutuzumab Sensitive : A2	venetoclax + obinutuzumab Sensitive: A2 - Guideline venetoclax + obinutuzumab Sensitive : A2
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
BCL2 elevation + IGH elevation	Follicular Lymphoma	BCL2 elevation + IGH elevation	Follicular Lymphoma	rituximab Resistant: B - Late Trials rituximab Resistant : B	rituximab Resistant: B - Late Trials rituximab Resistant : B
IGH mutation	Small Lymphocytic Lymphoma	IGH mutation	Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: B - Late Trials rituximab + idelalisib Sensitive : B	rituximab + idelalisib Sensitive: B - Late Trials rituximab + idelalisib Sensitive : B
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: B - Late Trials obinutuzumab + acalabrutinib Sensitive : B	obinutuzumab + acalabrutinib Sensitive: B - Late Trials obinutuzumab + acalabrutinib Sensitive : B
IGH mutation	Small Lymphocytic Lymphoma	IGH mutation	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
ATM mutation + IGH mutation	Chronic Lymphocytic Leukemia	ATM mutation + IGH mutation	Chronic Lymphocytic Leukemia	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
ATM mutation + IGH mutation	Chronic Lymphocytic Leukemia	ATM mutation + IGH mutation	Chronic Lymphocytic Leukemia	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
IGH mutation	Small Lymphocytic Lymphoma	IGH mutation	Small Lymphocytic Lymphoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
IGH mutation + Chr del(13q)	Chronic Lymphocytic Leukemia	IGH mutation + Chr del(13q)	Chronic Lymphocytic Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
IGH mutation + Chr del(11q)	Chronic Lymphocytic Leukemia	IGH mutation + Chr del(11q)	Chronic Lymphocytic Leukemia	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
IGH mutation	Chronic Lymphocytic Leukemia	IGH mutation	Chronic Lymphocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
IGH mutation + Chr del(8p)	Chronic Lymphocytic Leukemia	IGH mutation + Chr del(8p)	Chronic Lymphocytic Leukemia	fludarabine IV Resistant: C3 – Early Trials fludarabine IV Resistant : C3	fludarabine IV Resistant: C3 – Early Trials fludarabine IV Resistant : C3
IGH translocation	Acute Myelogenous Leukemia	IGH translocation	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Multiple Myeloma	IGH translocation	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH translocation	Lymphoma	IGH translocation	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC-IGH fusion	Chronic Lymphocytic Leukemia	MYC-IGH fusion	Chronic Lymphocytic Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC-IGH fusion	Chronic Myeloid Leukemia	MYC-IGH fusion	Chronic Myeloid Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
MYC-IGH fusion	Acute Myelogenous Leukemia	MYC-IGH fusion	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion + JAK2 R867Q	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
IGH-CRLF2 fusion	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
IGH-CRLF2 fusion + JAK2 GPInsR683	Childhood B Acute Lymphoblastic Leukemia	IGH-CRLF2 fusion + JAK2 GPInsR683	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D

IGH (Immunoglobulin Heavy Locus)

Associations(28)

Associations
(28)